FRA:UJ9 (China)
Â
Class H
€
0.57
+0.040 (+7.55%)
Jul 14
Business Description
Shandong Boan Biotechnology Co Ltd
ISIN : CNE100005RV4
Share Class Description:
FRA:UJ9: Class HTotal Employee Number:
696Compare
Compare
Traded in other countries / regions
06955.Hong KongUJ9.Germany IPO Date
2023-01-12Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.44 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 5.9 | |||||
Interest Coverage | 1.04 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.52 | |||||
Beneish M-Score | -2.23 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.2 | |||||
3-Year FCF Growth Rate | 24 | |||||
3-Year Book Growth Rate | 16.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.55 | |||||
9-Day RSI | 62.59 | |||||
14-Day RSI | 55.59 | |||||
3-1 Month Momentum % | -27.03 | |||||
6-1 Month Momentum % | -43.75 | |||||
12-1 Month Momentum % | -70.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.33 | |||||
Quick Ratio | 2.18 | |||||
Cash Ratio | 1.31 | |||||
Days Inventory | 238.58 | |||||
Days Sales Outstanding | 243.77 | |||||
Days Payable | 310.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.9 | |||||
Shareholder Yield % | -45.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.66 | |||||
Operating Margin % | 5.14 | |||||
Net Margin % | 0.89 | |||||
EBITDA Margin % | 17.01 | |||||
FCF Margin % | -26.7 | |||||
OCF Margin % | 8.21 | |||||
ROE % | 0.33 | |||||
ROA % | 0.2 | |||||
ROIC % | 1.63 | |||||
3-Year ROIIC % | 39.06 | |||||
ROC (Joel Greenblatt) % | 4.74 | |||||
ROCE % | 1.72 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 460.5 | |||||
Forward PE Ratio | 15.24 | |||||
PE Ratio without NRI | 460.5 | |||||
PS Ratio | 3.38 | |||||
PB Ratio | 1.04 | |||||
Price-to-Tangible-Book | 2.19 | |||||
Price-to-Operating-Cash-Flow | 41.18 | |||||
EV-to-EBIT | 56.32 | |||||
EV-to-EBITDA | 19.24 | |||||
EV-to-Revenue | 3.26 | |||||
EV-to-FCF | -10.95 | |||||
Price-to-GF-Value | 0.33 | |||||
Price-to-Graham-Number | 7.13 | |||||
| Price-to-Net-Current-Asset-Value | 4.75 | |||||
Earnings Yield (Greenblatt) % | 1.78 | |||||
FCF Yield % | -7.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shandong Boan Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 94.961 | ||
| EPS (TTM) (€) | 0.001 | ||
| Beta | 1.0394 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.74 | ||
| Volatility % | 69.5 | ||
| 14-Day RSI | 55.59 | ||
| 14-Day ATR (€) | 0.018305 | ||
| 20-Day SMA (€) | 0.52965 | ||
| 12-1 Month Momentum % | -70.81 | ||
| 52-Week Range (€) | 0.492 - 2.12 | ||
| Shares Outstanding (Mil) | 622.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shandong Boan Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shandong Boan Biotechnology Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shandong Boan Biotechnology Co Ltd Frequently Asked Questions
What is Shandong Boan Biotechnology Co Ltd(FRA:UJ9)'s stock price today?
The current price of FRA:UJ9 is €0.57. The 52 week high of FRA:UJ9 is €2.12 and 52 week low is €0.49.
When is next earnings date of Shandong Boan Biotechnology Co Ltd(FRA:UJ9)?
The next earnings date of Shandong Boan Biotechnology Co Ltd(FRA:UJ9) is .
Does Shandong Boan Biotechnology Co Ltd(FRA:UJ9) pay dividends? If so, how much?
Shandong Boan Biotechnology Co Ltd(FRA:UJ9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shandong Boan Biotechnology Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers